Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
Business Wire•18/10/2026•18:05 ET
0
Key Highlights
- ➤Incyte (INCY) will present four rapid oral oncology data sets at ESMO Congress 2026
- ➤INCB161734 KRAS G12D inhibitor data cover colorectal and pancreatic cancers
- ➤INCA33890 TGFβR2×PD-1 bispecific antibody data target microsatellite-stable colorectal cancer
- ➤INCB161734 and INCA33890 are being evaluated in ongoing Phase 3 programs
- ➤Incyte investor webcast scheduled October 26, 2026, to discuss ESMO data and portfolio updates
Expert Statements
Pablo J. Cagnoni, President, Incyte and Global Head of Research and Development
“The data being presented at ESMO further reinforce our confidence in these novel investigational approaches and their potential to improve and prolong the lives of patients with difficult-to-treat gastrointestinal cancers.”
Pablo J. Cagnoni, President, Incyte and Global Head of Research and Development
“Importantly, these findings not only provide new clinical insights, but they also inform our registrational development programs, including the Phase 3 KRAS G12D and TGFβR2×PD-1 studies already underway.”
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
Four rapid oral presentations at ESMO will feature new data for INCB161734, a KRAS G12D inhibitor, and INCA33890(1), a TGFβR2×PD-1 bispecific antibody
Get started
Create a free account to read the full story.